Ascentage Pharma Group International (NASDAQ:AAPG) Given “Buy” Rating at BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a note issued to investors on Thursday,Benzinga reports. They currently have a $48.00 price objective on the stock. BTIG Research’s target price suggests a potential upside of 124.98% from the company’s current price.

AAPG has been the topic of a number of other research reports. Oppenheimer started coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price on the stock. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $48.00.

Ascentage Pharma Group International Stock Down 4.7%

Shares of AAPG stock opened at $21.34 on Thursday. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The firm’s 50-day moving average is $24.10 and its two-hundred day moving average is $29.99. Ascentage Pharma Group International has a 12 month low of $17.56 and a 12 month high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million for the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, UBS Group AG lifted its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.